- Home
- MRAM vs BMEA Comparison
MRAM vs BMEA Comparison
Compare MRAM & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRAM
- BMEA
- Stock Information
- Founded
- MRAM 2008
- BMEA 2017
- Country
- MRAM United States
- BMEA United States
- Employees
- MRAM N/A
- BMEA N/A
- Industry
- MRAM Semiconductors
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- MRAM Technology
- BMEA Health Care
- Exchange
- MRAM Nasdaq
- BMEA Nasdaq
- Market Cap
- MRAM 130.3M
- BMEA 125.4M
- IPO Year
- MRAM 2016
- BMEA 2021
- Fundamental
- Price
- MRAM $5.26
- BMEA $2.65
- Analyst Decision
- MRAM Strong Buy
- BMEA Buy
- Analyst Count
- MRAM 2
- BMEA 13
- Target Price
- MRAM $9.00
- BMEA $27.92
- AVG Volume (30 Days)
- MRAM 123.3K
- BMEA 539.0K
- Earning Date
- MRAM 04-30-2025
- BMEA 05-01-2025
- Dividend Yield
- MRAM N/A
- BMEA N/A
- EPS Growth
- MRAM N/A
- BMEA N/A
- EPS
- MRAM 0.04
- BMEA N/A
- Revenue
- MRAM $50,402,000.00
- BMEA N/A
- Revenue This Year
- MRAM $8.17
- BMEA N/A
- Revenue Next Year
- MRAM N/A
- BMEA N/A
- P/E Ratio
- MRAM $145.49
- BMEA N/A
- Revenue Growth
- MRAM N/A
- BMEA N/A
- 52 Week Low
- MRAM $4.89
- BMEA $2.35
- 52 Week High
- MRAM $8.66
- BMEA $18.40
- Technical
- Relative Strength Index (RSI)
- MRAM 34.03
- BMEA 32.66
- Support Level
- MRAM $5.13
- BMEA $2.35
- Resistance Level
- MRAM $5.35
- BMEA $2.98
- Average True Range (ATR)
- MRAM 0.20
- BMEA 0.25
- MACD
- MRAM -0.02
- BMEA -0.01
- Stochastic Oscillator
- MRAM 15.35
- BMEA 20.35
About MRAM Everspin Technologies Inc.
Everspin Technologies Inc is a provider of Magnetoresistive Random Access Memory (MRAM) products. Its portfolio of MRAM technologies, including Toggle MRAM and Spin-transfer Torque MRAM (STT-MRAM), delivers superior performance, persistence, and reliability in non-volatile memories that transform how mission-critical data is protected against power loss. The company derives revenue from the sale of MRAM-based products in discrete unit form, licenses of and royalties on MRAM and magnetic sensor technology, the sale of backend foundry services, and design services to third parties. It recognizes revenue in three primary geographic regions; North America; Europe, the Middle East, and Africa (EMEA); and Asia-Pacific (APAC).
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.